Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

Feb. 5. 2025 – The FDA has approved a new pill to treat adults with a type of blood cancer called mantle cell lymphoma (MCL). This treatment is for people who are newly diagnosed or haven't h ...

The Food and Drug Administration (FDA) has granted traditional approval to Calquence (acalabrutinib) with bendamustine and Rituxan (rituximab) for adults with previously untreated mantle cell lymphoma ...

The agency also approved acalabrutinib as part of combination therapy for mantle cell lymphoma. The FDA approved two oncology regimens on Jan. 16. One is for a subset of patients with colorectal ...

“With today’s approval, Calquence provides a critical new treatment option to mantle cell lymphoma patients in the US, with Calquence proven to deliver nearly one and a half years of ...

Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk of disease progression or death by 27% in patients with previously ...

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

FDA Approves New Drug Combination for Mantle Cell LymphomaThe FDA has approved a new pill to treat adults with a type of blood cancer called mantle cell lymphoma (MCL).